Janssen Pharmaceutica N.V., Belgium clinical trials

Acquired by Johnson & Johnson

The registry lists 58 studies whose lead sponsor is Janssen Pharmaceutica N.V., Belgium. 1 are recruiting or about to start. Per ClinicalTrials.gov, last updated Sep 25, 2026.

Studies

Recruiting first, then most recently updated. Showing 50 of 58. List all 58 → · All Johnson & Johnson studies →

• A Study of Real-Life Current Standards of Care in Participants With Relapsed and/or Refractory Multiple MyelomaRecruitingNCT05160584

  Sponsor listed in the registry: Janssen Pharmaceutica N.V., Belgium · Janssen Pharmaceutica N.V., Belgium — acquired company within the Johnson & Johnson group

• A Study of JNJ-64042056 in Participants With Preclinical Alzheimer's DiseaseActive, not recruitingNCT06544616Phase 2

  Sponsor listed in the registry: Janssen Pharmaceutica N.V., Belgium · Janssen Pharmaceutica N.V., Belgium — acquired company within the Johnson & Johnson group

• A Study of Adding Apalutamide to Radiotherapy and LHRH Agonist in High-Risk Patients With Hormone-Sensitive Prostate CancerActive, not recruitingNCT04557059Phase 3

  Sponsor listed in the registry: Janssen Pharmaceutica N.V., Belgium · Janssen Pharmaceutica N.V., Belgium — acquired company within the Johnson & Johnson group

• A Study of Guselkumab and Interleukin-17 (IL-17) Inhibitor Therapies in Participants With Psoriatic Arthritis in Routine Clinical PracticeActive, not recruitingNCT05049798

  Sponsor listed in the registry: Janssen Pharmaceutica N.V., Belgium · Janssen Pharmaceutica N.V., Belgium — acquired company within the Johnson & Johnson group

• A Study of JNJ-55308942 in the Treatment of Bipolar DepressionCompletedNCT05328297Phase 2

  Sponsor listed in the registry: Janssen Pharmaceutica N.V., Belgium · Janssen Pharmaceutica N.V., Belgium — acquired company within the Johnson & Johnson group

• A Study in Chronic Hepatitis B e-Antigen Negative Participants After Discontinuation of Nucleos(t)Ide Analog (NA) TreatmentWithdrawnNCT05550519Early Phase 1

  Sponsor listed in the registry: Janssen Pharmaceutica N.V., Belgium · Janssen Pharmaceutica N.V., Belgium — acquired company within the Johnson & Johnson group

• A Study of JNJ-64140284 in Healthy Male ParticipantsTerminatedNCT04566926Phase 1

  Sponsor listed in the registry: Janssen Pharmaceutica N.V., Belgium · Janssen Pharmaceutica N.V., Belgium — acquired company within the Johnson & Johnson group

• A Study of Ponesimod in Healthy Adult ParticipantsCompletedNCT05552196Phase 1

  Sponsor listed in the registry: Janssen Pharmaceutica N.V., Belgium · Janssen Pharmaceutica N.V., Belgium — acquired company within the Johnson & Johnson group

• A Study of Ponesimod in Healthy Adult Participants Receiving Propranolol at Steady StateCompletedNCT03882255Phase 1

  Sponsor listed in the registry: Janssen Pharmaceutica N.V., Belgium · Janssen Pharmaceutica N.V., Belgium — acquired company within the Johnson & Johnson group

• A Study Evaluating Drug Drug Interaction Between Milvexian and Atorvastatin in Healthy ParticipantsCompletedNCT04388501Phase 1

  Sponsor listed in the registry: Janssen Pharmaceutica N.V., Belgium · Janssen Pharmaceutica N.V., Belgium — acquired company within the Johnson & Johnson group

• A Study of Milvexian in Healthy Adult FemalesCompletedNCT05706753Phase 1

  Sponsor listed in the registry: Janssen Pharmaceutica N.V., Belgium · Janssen Pharmaceutica N.V., Belgium — acquired company within the Johnson & Johnson group

• A Study of Guselkumab in Participants With Active Psoriatic Arthritis and an Inadequate Response to Anti-Tumor Necrosis Factor Alpha (Anti-TNF Alpha) TherapyCompletedNCT03796858Phase 3

  Sponsor listed in the registry: Janssen Pharmaceutica N.V., Belgium · Janssen Pharmaceutica N.V., Belgium — acquired company within the Johnson & Johnson group

• A Study to Evaluate the Effect of Renal Impairment on the Pharmacokinetics of JNJ-64041575 in Adult Participants With Various Degrees of Renal FunctionCompletedNCT03189498Phase 1

  Sponsor listed in the registry: Janssen Pharmaceutica N.V., Belgium · Janssen Pharmaceutica N.V., Belgium — acquired company within the Johnson & Johnson group

• A Study to Evaluate the Efficacy and Safety of Sirukumab in Confirmed Severe or Critical Confirmed Coronavirus Disease (COVID)-19CompletedNCT04380961Phase 2

  Sponsor listed in the registry: Janssen Pharmaceutica N.V., Belgium · Janssen Pharmaceutica N.V., Belgium — acquired company within the Johnson & Johnson group

• Study to Assess the Acceptability of Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) Fixed-Dose Combination (FDC) Tablets in Human Immunodeficiency Virus Type 1 (HIV-1) Infected Pediatric Participants, Using Matching Placebo TabletsCompletedNCT04006704Phase 1

  Sponsor listed in the registry: Janssen Pharmaceutica N.V., Belgium · Janssen Pharmaceutica N.V., Belgium — acquired company within the Johnson & Johnson group

• A Study on Assessment of STELARA and Tumor Necrosis Factor Alpha Inhibitor Therapies in Participants With Psoriatic ArthritisCompletedNCT02627768

  Sponsor listed in the registry: Janssen Pharmaceutica N.V., Belgium · Janssen Pharmaceutica N.V., Belgium — acquired company within the Johnson & Johnson group

• A Study to Evaluate the Effect of Renal Impairment on JNJ-64417184 and Its Two Minor Metabolites JNJ-68294291 and JNJ-65201526 in Adult ParticipantsTerminatedNCT04426357Phase 1

  Sponsor listed in the registry: Janssen Pharmaceutica N.V., Belgium · Janssen Pharmaceutica N.V., Belgium — acquired company within the Johnson & Johnson group

• A Study in Healthy Participants to Assess the Effect of Darunavir, Emtricitabine, and Tenofovir Alafenamide in the Presence of Cobicistat When Administered as a Fixed Dose Combination (Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide) Compared to the Co-administration of the Separate AgentsTerminatedNCT04236453Phase 1

  Sponsor listed in the registry: Janssen Pharmaceutica N.V., Belgium · Janssen Pharmaceutica N.V., Belgium — acquired company within the Johnson & Johnson group

• A Registry to Observe the Treatment of Prostate Cancer Under Routine Medical CareCompletedNCT02236637

  Sponsor listed in the registry: Janssen Pharmaceutica N.V., Belgium · Janssen Pharmaceutica N.V., Belgium — acquired company within the Johnson & Johnson group

• Abiraterone With Different Steroid Regimens for Side Effect Related to Mineralcorticoid Excess Prevention in Prostate Cancer Prior to ChemotherapyCompletedNCT01867710Phase 2

  Sponsor listed in the registry: Janssen Pharmaceutica N.V., Belgium · Janssen Pharmaceutica N.V., Belgium — acquired company within the Johnson & Johnson group

• A Study to Investigate the Impact of Abiraterone Acetate and Enzalutamide on Health-related Quality of Life, Participant-Reported Outcomes, and Medical Resource Use in Metastatic Castration-resistant Prostate Cancer ParticipantsCompletedNCT02813408

  Sponsor listed in the registry: Janssen Pharmaceutica N.V., Belgium · Janssen Pharmaceutica N.V., Belgium — acquired company within the Johnson & Johnson group

• Tracking Biologics Along the Silk RoadCompletedNCT03006198

  Sponsor listed in the registry: Janssen Pharmaceutica N.V., Belgium · Janssen Pharmaceutica N.V., Belgium — acquired company within the Johnson & Johnson group

• Telaprevir With Peginterferon Alfa & Ribavirin in Ex-People Who INject Drugs Infected by Genotype 1 Chronic Hepatitis CCompletedNCT01980290

  Sponsor listed in the registry: Janssen Pharmaceutica N.V., Belgium · Janssen Pharmaceutica N.V., Belgium — acquired company within the Johnson & Johnson group

• Idylla IFV-RSV Panel Clinical TestingCompletedNCT02786381

  Sponsor listed in the registry: Janssen Pharmaceutica N.V., Belgium · Janssen Pharmaceutica N.V., Belgium — acquired company within the Johnson & Johnson group

• A Study to Record in an Observational Manner the Treatment of Multiple Myeloma as it is Being Done in Every Day Practice Without Providing Any Investigational Drug or Prescribing Any ProcedureCompletedNCT01241396

  Sponsor listed in the registry: Janssen Pharmaceutica N.V., Belgium · Janssen Pharmaceutica N.V., Belgium — acquired company within the Johnson & Johnson group

• Clinical Assessment and Psychosocial Impact of PsoriasisCompletedNCT01964443

  Sponsor listed in the registry: Janssen Pharmaceutica N.V., Belgium · Janssen Pharmaceutica N.V., Belgium — acquired company within the Johnson & Johnson group

• Non-Interventional Study of Participants With Newly Diagnosed Schizophrenia Treated With Paliperidone PalmitateCompletedNCT02532842

  Sponsor listed in the registry: Janssen Pharmaceutica N.V., Belgium · Janssen Pharmaceutica N.V., Belgium — acquired company within the Johnson & Johnson group

• The Prolonged Use of Topiramate for Preventing Migraine HeadachesCompletedNCT00216619Phase 3

  Sponsor listed in the registry: Janssen Pharmaceutica N.V., Belgium · Janssen Pharmaceutica N.V., Belgium — acquired company within the Johnson & Johnson group

• A Study of the Effectiveness and Safety of Sustained-release Hydromorphone (a Strong Opioid) in Patients With Chronic Noncancer Pain.CompletedNCT00261495Phase 3

  Sponsor listed in the registry: Janssen Pharmaceutica N.V., Belgium · Janssen Pharmaceutica N.V., Belgium — acquired company within the Johnson & Johnson group

• A Study to Evaluate the Efficacy and Safety of Risperidone for the Prevention of Mood Episodes in the Treatment of Patients With Bipolar I DisorderCompletedNCT00391222Phase 3

  Sponsor listed in the registry: Janssen Pharmaceutica N.V., Belgium · Janssen Pharmaceutica N.V., Belgium — acquired company within the Johnson & Johnson group

• A Study to Investigate the Effects of Itraconazole on the Pharmacokinetics of JNJ-42165279 in Healthy Male ParticipantsCompletedNCT02065739Phase 1

  Sponsor listed in the registry: Janssen Pharmaceutica N.V., Belgium · Janssen Pharmaceutica N.V., Belgium — acquired company within the Johnson & Johnson group

• Exploratory Study on the Mood and Cytokine Levels in Female Healthy Participants and Major Depressive Disorder PatientsCompletedNCT01533285Early Phase 1

  Sponsor listed in the registry: Janssen Pharmaceutica N.V., Belgium · Janssen Pharmaceutica N.V., Belgium — acquired company within the Johnson & Johnson group

• Long-acting Injectable Risperidone in Patients With Schizophrenia After an Acute EpisodeCompletedNCT00216671Phase 4

  Sponsor listed in the registry: Janssen Pharmaceutica N.V., Belgium · Janssen Pharmaceutica N.V., Belgium — acquired company within the Johnson & Johnson group

• Interaction Between Etravirine or Darunavir/Ritonavir and Artemether / LumefantrineCompletedNCT01876966Phase 1

  Sponsor listed in the registry: Janssen Pharmaceutica N.V., Belgium · Janssen Pharmaceutica N.V., Belgium — acquired company within the Johnson & Johnson group

• A Survey Study of the Treatment and Outcome Management in Patients Diagnosed With Alzheimer's DiseaseCompletedNCT00291421

  Sponsor listed in the registry: Janssen Pharmaceutica N.V., Belgium · Janssen Pharmaceutica N.V., Belgium — acquired company within the Johnson & Johnson group

• A Pilot Study of the Use of Risperidone Long Acting Injectable in the Treatment of Patients With Recent Onset PsychosisCompletedNCT00216580Phase 3

  Sponsor listed in the registry: Janssen Pharmaceutica N.V., Belgium · Janssen Pharmaceutica N.V., Belgium — acquired company within the Johnson & Johnson group

• A Study of Treatment Success in Changing From Olanzapine to Long-acting Injectable Risperidone (RISPERDAL® CONSTA™)CompletedNCT00216632Phase 4

  Sponsor listed in the registry: Janssen Pharmaceutica N.V., Belgium · Janssen Pharmaceutica N.V., Belgium — acquired company within the Johnson & Johnson group

• The Effect of JNJ-39393406 on Event Related Potentials in Stable Schizophrenic PatientsTerminatedNCT01137799Phase 1

  Sponsor listed in the registry: Janssen Pharmaceutica N.V., Belgium · Janssen Pharmaceutica N.V., Belgium — acquired company within the Johnson & Johnson group

• Retrospective Survey of Re-treatment With BortezomibCompletedNCT01524445

  Sponsor listed in the registry: Janssen Pharmaceutica N.V., Belgium · Janssen Pharmaceutica N.V., Belgium — acquired company within the Johnson & Johnson group

• The Effect of Nicotine on Arousal, Cognition and Social Cognition in Young and Elderly Healthy Subjects.CompletedNCT01181934Early Phase 1

  Sponsor listed in the registry: Janssen Pharmaceutica N.V., Belgium · Janssen Pharmaceutica N.V., Belgium — acquired company within the Johnson & Johnson group

• The Effect of Nicotine on Arousal, Cognition and Social Cognition in Schizophrenic PatientsCompletedNCT01186471Early Phase 1

  Sponsor listed in the registry: Janssen Pharmaceutica N.V., Belgium · Janssen Pharmaceutica N.V., Belgium — acquired company within the Johnson & Johnson group

• Treatment of Severe Alzheimer's Disease: Evaluation of Efficacy and Safety of Galantamine Hydrobromide in a Controlled StudyCompletedNCT00216593Phase 3

  Sponsor listed in the registry: Janssen Pharmaceutica N.V., Belgium · Janssen Pharmaceutica N.V., Belgium — acquired company within the Johnson & Johnson group

• A Study of the Effectiveness and Safety of Prolonged-release Methylphenidate Hydrochloride in Adult Patients With Attention Deficit/Hyperactivity Disorder.CompletedNCT00246220Phase 3

  Sponsor listed in the registry: Janssen Pharmaceutica N.V., Belgium · Janssen Pharmaceutica N.V., Belgium — acquired company within the Johnson & Johnson group

• A Study of the Effect on Pain Control of Treatment With Fentanyl, Administered Through the Skin, Compared With Placebo in Patients With OsteoarthritisCompletedNCT00236366Phase 4

  Sponsor listed in the registry: Janssen Pharmaceutica N.V., Belgium · Janssen Pharmaceutica N.V., Belgium — acquired company within the Johnson & Johnson group

• A 15-day Study to Assess the Safety and Clinical Utility of Duragesic (Fentanyl Transdermal Patch) in the Treatment of Children With Continuous Pain Requiring Narcotic Pain Relief TherapyCompletedNCT00271414Phase 3

  Sponsor listed in the registry: Janssen Pharmaceutica N.V., Belgium · Janssen Pharmaceutica N.V., Belgium — acquired company within the Johnson & Johnson group

• Treatment With Risperidone Long Acting Injectable (RLAI) in an Early Phase of PsychosisCompletedNCT00369239Phase 4

  Sponsor listed in the registry: Janssen Pharmaceutica N.V., Belgium · Janssen Pharmaceutica N.V., Belgium — acquired company within the Johnson & Johnson group

• EPO-BUL-01 - Study of the Optimization of Anemia Management of EPREX (Epoetin Alfa) in Predialysis Patients With Chronic Renal FailureCompletedNCT00338000Phase 4

  Sponsor listed in the registry: Janssen Pharmaceutica N.V., Belgium · Janssen Pharmaceutica N.V., Belgium — acquired company within the Johnson & Johnson group

• The Effectiveness and Safety of Topiramate on Prevention of Chronic MigraineCompletedNCT00216606Phase 3

  Sponsor listed in the registry: Janssen Pharmaceutica N.V., Belgium · Janssen Pharmaceutica N.V., Belgium — acquired company within the Johnson & Johnson group

• A Study of the Safety and Effectiveness of Risperidone Versus Placebo for the Treatment of Conduct Disorder in Children With Mild, Moderate, or Borderline Mental RetardationCompletedNCT00266552Phase 3

  Sponsor listed in the registry: Janssen Pharmaceutica N.V., Belgium · Janssen Pharmaceutica N.V., Belgium — acquired company within the Johnson & Johnson group

• A Study of the Safety and Effectiveness of Risperidone for the Treatment of Conduct Disorder and Other Disruptive Behavior Disorders in Children Ages 5 to 12 With Mild, Moderate, or Borderline Mental RetardationCompletedNCT00250354Phase 3

  Sponsor listed in the registry: Janssen Pharmaceutica N.V., Belgium · Janssen Pharmaceutica N.V., Belgium — acquired company within the Johnson & Johnson group